pathological processes leading to COPD for over 35 years, and based on the data available thus far, I see great potential in this 'anti-platelet' approach," said Robert A. Stockley
, MD, DSc, Professor of Medicine at the University Hospital Birmingham and one of the scientists who will study the samples in collaboration with the Carolus team. "If we are successful in our efforts to link the heteromer to AAT COPD, we could open up a completely new way to treat both the rare, genetic form of COPD as well as the more common type, which is the fourth leading cause of death worldwide."
Carolus' lead compound, CT-2009, selectively targets the heteromer, which has been shown in preclinical efforts to be present and elevated in AAT and COPD patient samples. The goals of the collaborative effort between Carolus and TAP will be to understand, among other things, whether the concentration of the heteromer is related to the severity and progression of disease, and eventually whether heteromer levels can be successfully modulated by CT-2009 in patients.
"Novel targets for disease present significant opportunities for more effective and safer treatments for patients. However, they may represent risky, unproven territory," noted Court R. Turner, CEO of Carolus Therapeutics. "Validating such targets in humans is a significant milestone to building value in the compounds. With this collaboration, we will have the opportunity to validate the heteromer as a target for AATD COPD specifically, and, perhaps, COPD in general."
CT-2009, is an IND-ready molecule that selectively disrupts the RANTES:PF4 heteromer with potential therapeutic utility in respiratory, pulmonary, cardiovascular and other indications. Initial focus with CT-2009 has been on Alpha-1 Antitrypsin Deficiency (and COPD) and Cystic Fibrosis. CT-2009 has demonstrated robust preclinical efficacy in relevant animals models of these diseases.
Page: 1 2 3 Related medicine technology :1
|SOURCE Carolus Therapeutics, Inc.|
Copyright©2012 PR Newswire.
All rights reserved
. Echo Therapeutics Announces Management Changes2
. aTyr Pharma Awarded Two Patents from USPTO to Support Development of New Therapeutics Based on Physiocrine Biology3
. aTyr Pharma Expands Executive Leadership Team to Support Development of New Therapeutics Based on Physiocrine Biology4
. Arcturus Therapeutics Acquires Cutting-Edge UNA Patent Estate from Marina Biotech5
. PTC Therapeutics Reports Second Quarter 2013 Financial and Corporate Results6
. Aratana Therapeutics Reports Second Quarter 2013 Financial Results7
. Breckenridge Enters Into Agreement to Acquire Certain Cypress Assets from Pernix Therapeutics8
. Northwest Biotherapeutics Announces Registered Direct Offering9
. Nektar Therapeutics Reports Financial Results for the Second Quarter of 201310
. Echo Therapeutics Announces Second Quarter 2013 Financial Results11
. Pain Therapeutics - Drugs, Markets and Companies - 2013 Report